1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178.
3. Kim OB, Yoon H. Prevalence of urinary incontinence, single voided volume, post void residual volume, daytime frequency, and nocturia in women over 40 years. Korean J Adult Nurs 2013;25:679-689.
6. Keane DP, O'Sullivan S. Urinary incontinence: anatomy, phy-siology and pathophysiology. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:207-226.
7. Cheater FM, Castleden CM. Epidemiology and classification of urinary incontinence. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:183-205.
8. Dowling-Castronovo A, Specht JK. How to try this: assess-ment of transient urinary incontinence in older adults. Am J Nurs 2009;109:62-71.
10. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine: a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997;327:195-207.
11. Fusgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther 2000;38:223-234.
12. Alabaster VA. Discovery & development of selective M3 anta-gonists for clinical use. Life Sci 1997;60:1053-1060.
13. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evalua-tion of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006;26:1694-1702.
15. Buyse G, Waldeck K, Verpoorten C, Bjork H, Casaer P, Andersson KE. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998;160((3 Pt 1):892-896.
16. Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatano A, Takahashi K, Nomura S. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 1999;288:1367-1373.
17. Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C. Efficacy and tolera-bility of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-295.
18. Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 2012;62:834-840.
19. Zat'ura F, Vsetica J, Abadias M, Pavlik I, Schraml P, Brod'ak M, Villoria J, Sust M. E-4018/CL50 Study Group. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. Eur Urol 2010;57:145-152.
21. Lin HH, Sheu BC, Lo MC, Huang SC. Comparison of treat-ment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynaecol 1999;106:1089-1092.
22. Bump RC, Voss S, Beardsworth A, Manning M, Zhao YD, Chen W. Long-term efficacy of duloxetine in women with stress urinary incontinence. BJU Int 2008;102:214-218.
24. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopau-sal women. Cochrane Database Syst Rev 2012;10:CD001405.